Orebriton (Ticagrelor)

Ticagrelor, the active ingredient in Orebriton, is a platelet aggregation inhibitor presented as a 90 mg tablet for oral use. It reduces the risk of thrombotic cardiovascular events in patients with acute coronary syndrome. GNH USA supplies Orebriton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Orebriton as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Orebriton is an antiplatelet medication that acts on the platelet P2Y12 receptor pathway to prevent clot formation.

- Acute coronary syndrome: Reduces the risk of cardiovascular death, myocardial infarction and stroke. - Post‑percutaneous coronary intervention (PCI): Prevents stent thrombosis and related ischemic events. - Secondary prevention after myocardial infarction: Lowers the risk of recurrent ischemic events.

Ticagrelor may cause a range of adverse reactions, most of which are mild to moderate in intensity.

Common Side Effects: - Dyspnea: Short‑term  short‑  short  short  short  short  short  short  short  short  … - Bruising or  … - Nausea - Headache - Diarrhea - Increased  …

Serious or Rare Side Effects: - Severe         t      t  t   t  t  t  t  t  lank  t  t   t  t   ewline